Risk factors
Sarepta Therapeutics (SRPT) risk factors
Item 1A of every Sarepta Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
69 risks, 12 new, 13 dropped, 26 reworded since the prior year. New risks center on ELEVIDYS and SRP-9004 fatal liver events, boxed warnings, and resulting adoption uncertainty.
Filed Mar 02, 2026 - FY2024 10-K risk factors
70 risks. Sarepta faces heavy risks around commercial adoption, regulatory approval conditions, and third-party manufacturing dependencies for its rare disease therapies. The company relies heavily on maintaining reimbursement coverage and navigating strict post-approval requirements for products like Elevidys and its PMO portfolio.
Filed Feb 28, 2025